Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $92M (up 28.7% year over year) with net income of −$31M.
Q2 2026 key financials · XBRL
- Revenue
- $92M
- +28.7% YoY · +10.8% QoQ
- Net income
- −$31M
- −1513.1% YoY · −1492.2% QoQ
- Operating margin
- 5.6%
- EPS (diluted)
- −$0.18
- −1700.0% YoY · −1900.0% QoQ
Source: XBRL data from the Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 10-Q on SEC EDGAR. USD.
Xeris Biopharma Holdings, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Investing cash used $534 thousand vs $292 thousand YoY, reflecting higher capital expenditures
- Financing cash used $6.9 million vs $2.2 million YoY
- Stock withheld-tax repurchases $17.2 million, offset by $10.3 million equity proceeds
Risk Factors
- No material risk-factor changes since the December 31, 2025 Form 10-K
- Carried-forward risks may materially affect business, consolidated financial statements, results, and cash flows
- Additional unknown or currently immaterial risks could impair business operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xeris Biopharma Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.